Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists-Reference-Cited by-同舟云学术

Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists

Published:2022-05 Issue:5 Volume:53 Page:1813-1822
ISSN:0039-2499
Container-title:Stroke
language:en
Short-container-title:Stroke

Author:

Goldenberg Ronald M.¹^ORCID,Cheng Alice Y.Y.²^ORCID,Fitzpatrick Tess³^ORCID,Gilbert Jeremy D.⁴^ORCID,Verma Subodh⁵^ORCID,Hopyan Julia J.⁶^ORCID

Affiliation:

1. LMC Diabetes & Endocrinology, Canada (R.M.G.).

2. Trillium Health Partners, St Michael’s Hospital, University of Toronto, Canada (A.Y.Y.C.).

3. Mackenzie Health, Canada (T.F.).

4. Sunnybrook Health Sciences Centre, University of Toronto, Canada (J.D.G.).

5. St Michael’s Hospital, University of Toronto, Canada (S.V.).

6. Sunnybrook Health Sciences Centre, University of Toronto, Canada (J.J.H.).

Abstract

People living with diabetes are at higher risk for stroke and have a poorer prognosis following a stroke event than those without diabetes. Data from cardiovascular outcome trials and meta-analyses indicate that GLP-1RAs (glucagon-like peptide 1 receptor agonists) reduce the risk of stroke in individuals with type 2 diabetes. Accordingly, many guidelines now recommend the addition of GLP-1RAs to ongoing antihyperglycemic regimens to lower the risk of stroke in type 2 diabetes. The current work summarizes evidence supporting the use of GLP-1RAs for stroke reduction in people with type 2 diabetes and offers 2 new resources for neurologists who are considering GLP-1RAs for their patients—a list of frequently asked questions with evidence-based answers on safely initiating and managing GLP-1RAs, and a practical decision-making algorithm to assist in using GLP-1RAs as part of a stroke reduction strategy.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Advanced and Specialized Nursing,Cardiology and Cardiovascular Medicine,Neurology (clinical)

Reference67 articles.

1. Diabetes Mellitus

2. The Role of HbA1c Determination in Detecting Unknown Glucose Disturbances in Ischemic Stroke

3. Prevalence of Abnormal Glucose Tolerance Following a Transient Ischemic Attack or Ischemic Stroke

4. Impact of Diabetes on Stroke Risk and Outcomes

5. Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperglycemia and Venous Thromboembolism;Diagnostics;2024-09-09

2. Rising to the challenge of cardio-renal-metabolic disease in the 21st century: Translating evidence into best clinical practice to prevent and manage atherosclerosis;Atherosclerosis;2024-09

3. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases;European Heart Journal;2024-08-30

4. Multidisciplinary Diabetes Management and Education Strategies in the Inpatient Rehabilitation Setting;Diabetes Spectrum;2024-08-01

5. Unveiling the Potential Role of Glucagon-Like Peptide-1 (Glp-1) Receptor Agonists in Offering Protection of the Cardiovascular, Renal, and Neural Systems: An Updated Narrative Review;Cureus;2024-07-31